1. Methods for prevention of acute post-endoscopic retrograde cholangiopancreatography pancreatitis
- Author
-
Kamil Jaszczuk, Michal Lipinski, and Grażyna Rydzewska
- Subjects
medicine.medical_specialty ,endoscopic retrograde cholangiopancreatography ,pancreatic duct stents ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,medicine ,post-endoscopic retrograde cholangiopancreatography pancreatitis ,Pancreatic duct ,Review Paper ,nonsteroidal anti-inflammatory drugs ,Nonsteroidal ,Endoscopic retrograde cholangiopancreatography ,medicine.diagnostic_test ,business.industry ,Gastroenterology ,medicine.disease ,Surgery ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,Medicine ,Pancreatitis ,Acute pancreatitis ,030211 gastroenterology & hepatology ,Complication ,business - Abstract
Acute pancreatitis is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), with incidence rates ranging between 2% and 16%. In addition to being experienced in endoscopic procedures and having knowledge of the patient qualification criteria, physicians should also be aware of the patient and procedure-related risk factors responsible for post-ERCP pancreatitis (PEP). Intrarectal administration of nonsteroidal anti-inflammatory drugs and pancreatic duct stenting were demonstrated to be efficient in high-risk patients. This review provides a broader summary of pharmacological methods and techniques aimed at reducing the risk of PEP.
- Published
- 2020